Summary by Futu AI
Panbela Therapeutics, Inc., a biopharmaceutical company, has filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC) on January 5, 2024. The filing pertains to the registration of additional securities under the company's 2016 Omnibus Incentive Plan. The plan, initially approved by shareholders on May 17, 2016, and subsequently amended on May 19, 2020, allows for an annual increase in the number of shares available for issuance. The increase is determined by the lesser of a set percentage of fully diluted shares or a number decided by the Board of Directors or its Compensation Committee. Effective January 1, 2024, an additional 3,275,155 shares of common stock have been made available under the plan. The registration statement includes references to the company's restated certificate of incorporation, bylaws, and opinions from legal counsel, among other exhibits. The company's executive officers, including President and CEO Jennifer K. Simpson, have signed the registration statement, indicating compliance with the requirements for filing on Form S-8.